
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio Inc. presents an attractive investment opportunity based on its positive interim clinical data, indicating efficacy in treating serious immune-related disorders, particularly in the areas of fibrogenesis and lung function. The company's lead programs, GRI-0621 and GRI-0803, are uniquely positioned in the biotech space to address significant unmet medical needs, which enhances the potential for strong future revenue streams. Additionally, despite adjustments in price targets, the underlying net present value (NPV) analysis reflects substantial upside potential from the current stock price, making GRI Bio's valuation compelling in light of the associated risks and rewards.
Bears say
GRI Bio Inc has reported a significant net loss of $3.4 million (EPS of $(1.28)) and $3.9 million (EPS of $(7.72)), which exceeded both its internal estimates and consensus expectations, indicating persistent financial underperformance. The company faces multiple risks, including liquidity and balance sheet concerns, the potential failure of its product candidates in clinical trials, and uncertain regulatory approvals, all of which could hinder its growth and commercialization efforts. Additionally, a complex competitive landscape and varying investor sentiment towards biotech stocks further contribute to a negative outlook on GRI Bio's financial sustainability and stock performance.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares